Landing
Pediatric Academic Societies (PAS) 2025
Pegcetacoplan for adolescents with C3G or primary IC-MPGN: VALIANT phase 3 double-blind placebo-controlled trial subgroup analysis
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.